Was Your Baby’s Cleft Palate Caused By Zofran?
Were you prescribed Zofran during the first trimester of pregnancy? It is possible that your child’s birth defects, such as cleft palate, were the result of this medication.
You may be entitled to compensation for your child’s injuries. Kelley Ferraro, LLC, has a long history of fighting negligent corporations that cause injuries to consumers. We are currently investigating cases involving cleft palate and Zofran. Our defective drug lawyers have the experience and skill to hold the drug’s manufacturer liable for the harm it has caused. Please speak with us today to learn how we may help your family.
Off-Label Use In Pregnant Women Has Been Linked To Cleft Palates In Babies
Zofran is manufactured by GlaxoSmithKline. The generic name of the medication is ondansetron. It was created to treat chemotherapy and radiation patients for the side effects of nausea and vomiting. Zofran is also used for post-surgical patients who are having side effects caused by pain medication. The drug is approved for these uses.
However, Zofran was also prescribed to pregnant women in an FDA-unapproved or off-label use to treat nausea and vomiting.
A number of studies now show that taking Zofran during the first trimester of pregnancy increases the risk of birth defects, including cleft palate. Researchers at Boston University and Harvard University conducted a review of over 10,000 birth records. The review revealed that having a baby with a cleft palate was more than twice as likely in women who took Zofran during pregnancy.
Why Do You Need Compensation?
Children with a cleft palate will need surgery to repair the defect, typically within the first 18 months. Some people born with a cleft palate will need additional surgeries throughout their lives. Your family will need compensation to cover these medical expenses as well as any additional losses such as pain and suffering.
Let our attorneys help. We offer free consultations. You can call us at 216-238-8654. You may also contact us online.
